Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.

Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H, Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H.

J Cardiol. 2011 Mar;57(2):194-201. doi: 10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17.

2.

Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.

Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H.

Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26.

PMID:
24763934
3.
4.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
5.

Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation.

Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, Hoshino K, Aoki T, Nishimura Y, Tamaru S, Ito M, Nishikawa M; McLordd Group.

Circ J. 2013;77(6):1436-44. Epub 2013 Mar 8.

6.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
7.

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.

Hokimoto S, Akasaka T, Tabata N, Arima Y, Tsujita K, Sakamoto K, Kaikita K, Morita K, Kumagae N, Yamamoto E, Oniki K, Nakagawa K, Ogawa H.

Thromb Res. 2015 Jun;135(6):1081-6. doi: 10.1016/j.thromres.2015.03.033. Epub 2015 Apr 11.

PMID:
25891840
8.

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.

Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.

J Cardiol. 2013 Sep;62(3):158-64. doi: 10.1016/j.jjcc.2013.03.006. Epub 2013 Jul 22.

9.

CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, Ong TK, Fong AY.

Int J Clin Pharm. 2013 Aug;35(4):621-8. doi: 10.1007/s11096-013-9783-y. Epub 2013 May 10.

PMID:
23661171
10.

Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.

Zou JJ, Xie HG, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Wang GJ.

Eur J Clin Pharmacol. 2013 Apr;69(4):771-7. doi: 10.1007/s00228-012-1392-5. Epub 2012 Sep 22.

PMID:
23001453
11.

Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.

Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS.

Heart. 2011 Apr;97(8):641-7. doi: 10.1136/hrt.2010.216499. Epub 2011 Feb 22.

PMID:
21345843
12.

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.

13.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
14.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

15.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS.

JAMA. 2011 Nov 23;306(20):2221-8. doi: 10.1001/jama.2011.1703. Epub 2011 Nov 16.

PMID:
22088980
16.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
17.

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

Hokimoto S, Mizobe M, Akasaka T, Arima Y, Kaikita K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9.

PMID:
24440142
18.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
19.

CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.

Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ.

Pharmazie. 2013 Mar;68(3):183-6.

PMID:
23556336
20.

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS.

Heart. 2012 Jan;98(2):139-44. doi: 10.1136/hrt.2011.227272. Epub 2011 Jun 23.

PMID:
21700758

Supplemental Content

Support Center